These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16296748)

  • 1. Bioadhesive properties of pegylated nanoparticles.
    Yoncheva K; Gómez S; Campanero MA; Gamazo C; Irache JM
    Expert Opin Drug Deliv; 2005 Mar; 2(2):205-18. PubMed ID: 16296748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of bioadhesive potential and intestinal transport of pegylated poly(anhydride) nanoparticles.
    Yoncheva K; Guembe L; Campanero MA; Irache JM
    Int J Pharm; 2007 Apr; 334(1-2):156-65. PubMed ID: 17118588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties.
    Yoncheva K; Lizarraga E; Irache JM
    Eur J Pharm Sci; 2005 Apr; 24(5):411-9. PubMed ID: 15784331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(vinyl methyl ether/maleic anhydride)-Doped PEG-PLA Nanoparticles for Oral Paclitaxel Delivery To Improve Bioadhesive Efficiency.
    Wang Q; Li C; Ren T; Chen S; Ye X; Guo H; He H; Zhang Y; Yin T; Liang XJ; Tang X
    Mol Pharm; 2017 Oct; 14(10):3598-3608. PubMed ID: 28892400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo study of the mucus-permeating properties of PEG-coated nanoparticles following oral administration.
    Inchaurraga L; Martín-Arbella N; Zabaleta V; Quincoces G; Peñuelas I; Irache JM
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):280-9. PubMed ID: 25541441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties.
    Arbós P; Campanero MA; Arangoa MA; Renedo MJ; Irache JM
    J Control Release; 2003 Apr; 89(1):19-30. PubMed ID: 12695060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of the bioadhesive properties of protein-coated PVM/MA nanoparticles.
    Arbós P; Arangoa MA; Campanero MA; Irache JM
    Int J Pharm; 2002 Aug; 242(1-2):129-36. PubMed ID: 12176235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the cytotoxicity, genotoxicity and mucus permeation capacity of several surface modified poly(anhydride) nanoparticles designed for oral drug delivery.
    Iglesias T; López de Cerain A; Irache JM; Martín-Arbella N; Wilcox M; Pearson J; Azqueta A
    Int J Pharm; 2017 Jan; 517(1-2):67-79. PubMed ID: 27908629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of bioadhesive amino-pegylated poly(anhydride) nanoparticles designed for oral DNA delivery.
    Yoncheva K; Centelles MN; Irache JM
    J Microencapsul; 2008 Mar; 25(2):82-9. PubMed ID: 18246486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioadhesive properties of Gantrez nanoparticles.
    Irache JM; Huici M; Konecny M; Espuelas S; Campanero MA; Arbos P
    Molecules; 2005 Jan; 10(1):126-45. PubMed ID: 18007282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin loaded mucus permeating nanoparticles: Addressing the surface characteristics as feature to improve mucus permeation.
    Pereira de Sousa I; Moser T; Steiner C; Fichtl B; Bernkop-Schnürch A
    Int J Pharm; 2016 Mar; 500(1-2):236-44. PubMed ID: 26802494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioadhesion and oral absorption of enoxaparin nanocomplexes.
    Sun W; Mao S; Wang Y; Junyaprasert VB; Zhang T; Na L; Wang J
    Int J Pharm; 2010 Feb; 386(1-2):275-81. PubMed ID: 19958824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study.
    Zabaleta V; Ponchel G; Salman H; Agüeros M; Vauthier C; Irache JM
    Eur J Pharm Biopharm; 2012 Aug; 81(3):514-23. PubMed ID: 22516136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles.
    Yuan H; Chen CY; Chai GH; Du YZ; Hu FQ
    Mol Pharm; 2013 May; 10(5):1865-73. PubMed ID: 23495754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain.
    Parikh T; Bommana MM; Squillante E
    Eur J Pharm Biopharm; 2010 Mar; 74(3):442-50. PubMed ID: 19941957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioadhesive mannosylated nanoparticles for oral drug delivery.
    Salman HH; Gamazo C; Campanero MA; Irache JM
    J Nanosci Nanotechnol; 2006; 6(9-10):3203-9. PubMed ID: 17048537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of polymer architecture on surface properties, plasma protein adsorption, and cellular interactions of pegylated nanoparticles.
    Sant S; Poulin S; Hildgen P
    J Biomed Mater Res A; 2008 Dec; 87(4):885-95. PubMed ID: 18228249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and characterization of mucoadhesive nanoparticles of poly (methyl vinyl ether-co-maleic anhydride) containing glycyrrhizic acid intended for vaginal administration.
    Aguilar-Rosas I; Alcalá-Alcalá S; Llera-Rojas V; Ganem-Rondero A
    Drug Dev Ind Pharm; 2015; 41(10):1632-9. PubMed ID: 25391332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uptake and Transport of Ultrafine Nanoparticles (Quantum Dots) in the Nasal Mucosa.
    Bejgum BC; Donovan MD
    Mol Pharm; 2021 Jan; 18(1):429-440. PubMed ID: 33346666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems?
    Illum L
    J Pharm Sci; 2007 Mar; 96(3):473-83. PubMed ID: 17117404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.